OPKO Health establishes minority stake in Xenetic Bio

• Noted biotech investor Dr. Philip Frost's OPKO Health (NASDAQ:OPK -1.7%) acquires a 6.3% interest in Xenetic Biosciences (XBIO +13.6%), a developer of next-generation biologics and cancer-focused therapeutics.
• Xenetic's product candidates include ErepoXen for the treatment of anemia, OncoHist for certain blood cancers, PulmoXen for cystic fibrosis and a Factor VIII for hemophilia (with Baxalta).